{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:00:29Z","timestamp":1791388829395,"version":"4.3.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor treatment. We compared CD3\u2009+\u2009, CD4\u2009+\u2009, CD8\u2009+\u2009, CD20\u2009+\u2009, CD57\u2009+\u2009, PD-1\u2009+\u2009and PD-L1\u2009+\u2009lymphocyte infiltrates in liver biopsies of patients that encountered VBDS (<jats:italic>n<\/jats:italic>\u2009=\u20092) or hepatotoxicity (<jats:italic>n<\/jats:italic>\u2009=\u20093) after pembrolizumab (<jats:italic>n<\/jats:italic>\u2009=\u20094) or nivolumab (<jats:italic>n<\/jats:italic>\u2009=\u20091) treatment with samples from normal liver (<jats:italic>n<\/jats:italic>\u2009=\u200910), non-alcohol steatohepatitis (NASH, <jats:italic>n<\/jats:italic>\u2009=\u200910), primary biliary cholangitis (PBC, <jats:italic>n<\/jats:italic>\u2009=\u200910) or pembrolizumab-treated patients without adverse events (<jats:italic>n<\/jats:italic>\u2009=\u20092). Notably, none of the cancer patients had primary nor metastatic liver tumors. We also studied direct growth effects of pembrolizumab on primary human intrahepatic biliary epithelial cells (HIBEpiC) in vitro. Liver sections of all checkpoint inhibitor- treated patients exhibited significantly higher CD3\u2009+\u2009infiltration than normal livers, and significantly higher PD-L1\u2009+\u2009, CD4\u2009+\u2009and CD8\u2009+\u2009infiltration, than other groups. PD-1\u2009+\u2009infiltration was significantly increased in livers of patients with severe hepatic adverse event. CD57\u2009+\u2009infiltration was similar in normal livers, NASH- and PBC groups, but highly increased in the checkpoint inhibitor-treated patients. Immune cell infiltrates were similar between NASH and normal livers. PBC samples had significantly higher CD3\u2009+\u2009, CD4\u2009+\u2009, CD8\u2009+\u2009and CD20\u2009+\u2009infiltrates than normal livers. HIBEpiC express PD-L1 but pembrolizumab did not affect their viability in vitro. Our findings suggest that VBDS is not due to direct cytotoxicity of checkpoint inhibitors and that the immunological attack against livers induced by these drugs is different from other cholestatic liver conditions.<\/jats:p>\n          <jats:p>Biological insight: Checkpoint inhibitors upregulate PD-1 and PD-L1, as well as cytotoxic CD57\u2009+\u2009cells in the non-cancerous liver tissues and this may be associated with checkpoint inhibitor-induced hepatotoxicity.<\/jats:p>","DOI":"10.1186\/s12865-025-00682-y","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:02:44Z","timestamp":1737590564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity"],"prefix":"10.1186","volume":"26","author":[{"given":"Miro","family":"Saarela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essi","family":"Parviainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"di Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Raunio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kankaanranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri","family":"Vuopala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"R\u00f6nk\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Nurmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raija","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri S.","family":"Selander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"682_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.apha.2021.01.002","volume":"91","author":"JB Jacob","year":"2021","unstructured":"Jacob JB, Jacob MK, Parajuli P. Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol. 2021;91:111\u201339.","journal-title":"Adv Pharmacol"},{"issue":"24","key":"682_CR2","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","volume":"28","author":"M Shah","year":"2022","unstructured":"Shah M, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer. Clin Cancer Res. 2022;28(24):5249\u201353.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"682_CR3","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2(4):e000268.","journal-title":"ESMO Open"},{"issue":"4","key":"682_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2217\/imt-2021-0078","volume":"14","author":"M Gemelli","year":"2022","unstructured":"Gemelli M, et al. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy. 2022;14(4):175\u201381.","journal-title":"Immunotherapy"},{"issue":"12","key":"682_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"key":"682_CR6","doi-asserted-by":"crossref","unstructured":"Spiers, L., N. Coupe, and M. Payne, Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford), 2019;58(Suppl 7): vii7-vii16.","DOI":"10.1093\/rheumatology\/kez418"},{"issue":"2","key":"682_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1159\/000507695","volume":"13","author":"T Thorsteinsdottir","year":"2020","unstructured":"Thorsteinsdottir T, et al. Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report. Case Rep Oncol. 2020;13(2):659\u201363.","journal-title":"Case Rep Oncol"},{"key":"682_CR8","doi-asserted-by":"crossref","unstructured":"Pi, B., et al., Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol, 2021;33(1S Suppl 1):e858-e867.","DOI":"10.1097\/MEG.0000000000002280"},{"issue":"2","key":"682_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/diagnostics12020539","volume":"12","author":"K Gourari","year":"2022","unstructured":"Gourari K, et al. A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. Diagnostics (Basel). 2022;12(2):539.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"682_CR10","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.","journal-title":"Sci Rep"},{"issue":"2","key":"682_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-012-2181-7","volume":"135","author":"J Tuomela","year":"2012","unstructured":"Tuomela J, et al. Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 2012;135(2):481\u201393.","journal-title":"Breast Cancer Res Treat"},{"key":"682_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","volume":"1","author":"A Bisht","year":"2025","unstructured":"Bisht A, et al. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv Transl Res. 2025;1:102\u201333.","journal-title":"Drug Deliv Transl Res."},{"key":"682_CR13","doi-asserted-by":"crossref","unstructured":"Millet A, et al. Analysis of Pembrolizumab in Human Plasma by LC-MS\/HRMS. Method Validation and Comparison with Elisa. Biomedicines. 2021;9(6):621.","DOI":"10.3390\/biomedicines9060621"},{"issue":"10","key":"682_CR14","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/j.jtho.2019.05.026","volume":"14","author":"K Kunimasa","year":"2019","unstructured":"Kunimasa K, et al. Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression. J Thorac Oncol. 2019;14(10):e231\u20133.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"682_CR15","doi-asserted-by":"publisher","first-page":"15312","DOI":"10.1038\/s41598-021-93479-z","volume":"11","author":"SJ Dart","year":"2021","unstructured":"Dart SJ, et al. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Sci Rep. 2021;11(1):15312.","journal-title":"Sci Rep"},{"issue":"4","key":"682_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","volume":"65","author":"H Kared","year":"2016","unstructured":"Kared H, et al. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016;65(4):441\u201352.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00682-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:02:47Z","timestamp":1737590567000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00682-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00682-y","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the declaration of Helsinki and was approved by the Regional Ethics Committee of Northern Ostrobothnia Hospital District, the Medical Research Ethics Committee of Wellbeing Services County of North Savo and the Ethics committee of IRCCS Humanitas Research Hospital, Rozzano, Italy. Informed consent was obtained from all participants, if alive. All studies were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}